[breadcrumb_custom]

Poseida Therapeutics Inc (NASDAQ:PSTX) Declines -68.54% In 2024; Is It Attractive Enough At $3.60?

In last trading session, Poseida Therapeutics Inc (NASDAQ:PSTX) saw 0.7 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price level of $3.60 trading at $0.22 or 6.51% at ring of the bell on the day assigns it a market valuation of $344.23M. That closing price of PSTX’s stock is at a discount of -138.06% from its 52-week high price of $8.57 and is indicating a premium of 57.22% from its 52-week low price of $1.54. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.91 million shares which gives us an average trading volume of 954.01K if we extend that period to 3-months.

Poseida Therapeutics Inc (NASDAQ:PSTX) trade information

Upright in the green during last session for gaining 6.51%, in the last five days PSTX remained trading in the green while hitting it’s week-highest on Tuesday, 02/06/24 when the stock touched $3.60 price level, adding 8.4% to its value on the day. Poseida Therapeutics Inc’s shares saw a change of 7.14% in year-to-date performance and have moved 3.15% in past 5-day. Poseida Therapeutics Inc (NASDAQ:PSTX) showed a performance of 12.85% in past 30-days. Number of shares sold short was 2.95 million shares which calculate 4.17 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Poseida Therapeutics Inc (PSTX) estimates and forecasts

Statistics highlight that Poseida Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 34.33% of value to its shares in past 6 months, showing an annual growth rate of -68.54% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -64.50% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $6.65 million for the same. And 3 analysts are in estimates of company making revenue of $14.2 million in the next quarter that will end on Mar 2024. Company posted $10.05 million and $10.34 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -33.80% while estimating it to be 37.30% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -21.82% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -68.54% while estimates for its earnings growth in next 5 years are of 2.70%.

PSTX Dividends

Poseida Therapeutics Inc is more likely to be releasing its next quarterly report between March 07 and March 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Poseida Therapeutics Inc (NASDAQ:PSTX)’s Major holders

Insiders are in possession of 34.56% of company’s total shares while institution are holding 48.08 percent of that, with stock having share float percentage of 73.48%. Investors also watch the number of corporate investors in a company very closely, which is 48.08% institutions for Poseida Therapeutics Inc that are currently holding shares of the company. FMR, LLC is the top institutional holder at PSTX for having 13.04 million shares of worth $46.93 million. And as of Sep 29, 2023, it was holding 13.63% of the company’s outstanding shares.

The second largest institutional holder is Pentwater Capital Management Lp, which was holding about 5.97 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 6.25% of outstanding shares, having a total worth of $21.51 million.

On the other hand, Fidelity Growth Company Fund and Fidelity Select Portfolios – Health Care are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 3.31 million shares of worth $11.93 million or 3.47% of the total outstanding shares. The later fund manager was in possession of 2.12 million shares on Dec 30, 2023, making its stake of worth around $7.63 million in the company or a holder of 2.22% of company’s stock.

On Key

Related Posts